Point Reached in Targeted Therapy; Where are we?
Point Reached in Targeted Therapy; Where are we?
Lung cancer is a very important public health problem. Identification of new molecular targets and development of novel therapies related to activated immune cytotoxic cells are significant steps in achieving the goal of personalized therapy in lung cancer.
___
- Yüce D, Kılıçkap S. Epidemiology and Etiology. Turkiye Klinikleri Radiat
Oncol-Special Topics 2018; 4: 1-7.
- Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling
of non-small-cell lung cancer: implications for current and future
therapies. J Clin Oncol 2013; 31: 1039-49. [CrossRef]
- Griffin R, Robert RA. Molecular Targets in Non-Small Cell Lung Cancer.
Ochsner J 2017; 17:388-92.
- Levy MA, Lovly CM, Pao W. Translating genomic information into
clinical medicine: Lung cancer as a paradigm. Genome Res 2012; 22:
2101-8. [CrossRef]
- Weinstein IB. Cancer. Addiction to oncogenes - The Achilles heal of
cancer. Science 2002; 297: 63-4. [CrossRef]
- Demir M, Kılıçkap S. Targeted Therapy and Biological Agents. Turkiye
Klinikleri Radiat Oncol-Special Topics 2018; 4: 86-92.
- Puri T. Targeted therapy in nonsmall cell lung cancer. Indian J Cancer
2017; 54: 83-8. [CrossRef]
- Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al.
A prospective, molecular epidemiology study of EGFR mutations
in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma
histology (PIONEER). J Thorac Oncol 2014; 9: 154-62.
[CrossRef]
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin 2011; 61: 69-90. [CrossRef]
- Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone
G, et al. Molecular testing guideline for selection of lung cancer patients
for EGFR and ALK tyrosine kinase inhibitors: Guideline from
the College of American Pathologists, International Association for
the Study of Lung Cancer, and Association for Molecular Pathology.
J Thorac Oncol 2013; 8: 823-59. [CrossRef]
- Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):
a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol 2011; 12: 735-42. [CrossRef]
- Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E,
et al. Erlotinib versus standard chemotherapy as first-line treatment
for European patients with advanced EGFR mutation-positive nonsmall-cell
lung cancer (EURTAC): a multicentre, open-label, randomised
phase 3 trial. Lancet Oncol 2012; 13: 239-46. [CrossRef]
- Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, et al. First-line erlotinib
versus gemcitabine/cisplatin in patients with advanced EGFR
mutation-positive nonsmall-cell lung cancer: analyses from the
phase III, randomized, open-label, ENSURE study. Ann Oncol 2015;
26: 1883-9. [CrossRef]
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib
or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med 2009; 361: 947-57. [CrossRef]
- Maemondo M, Inoue A, Kobayashi K, Sugara S, Ouzimu S, Isobe H,
et al. Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med 2010; 362: 2380-8. [CrossRef]
- Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani
J, et al. Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor(WJTOG3405): an open label, randomised
phase 3 trial. Lancet Oncol 2010; 11: 121-8. [CrossRef]
- Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al.
Phase III study of afatinib or cisplatin plus pemetrexed in patients
with metastatic lung adenocarcinoma with EGFR mutations. J Clin
Oncol 2013; 31: 3327-34. [CrossRef]
- Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus
cisplatin plus gemcitabine for first-line treatment of Asian patients
with advanced nonsmall-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet
Oncol 2014; 15: 213-22. [CrossRef]
- Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et
al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive
lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
analysis of overall survival data from two randomised, phase 3 trials.
Lancet Oncol 2015; 16: 141-51. [CrossRef]
- Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib
versus gefitinib as first-line treatment of patients with EGFR mutation-positive
non-small-cell lung cancer (LUX-Lung 7): a phase 2B,
open-label,randomised controlled trial. Lancet Oncol 2016; 17: 577-
89. [CrossRef]
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattanna T, Chewaskulyong
B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced
Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 113-
25. [CrossRef]
- Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, et al.
Characteristics of lung cancers harboring NRAS mutations. Clin Cancer
Res 2013; 19: 2584-91. [CrossRef]
- Sequist LV, Waltman BA, Dias-Santagata D,Digumarthy S, Turke AB,
Fidias P, et al. Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:
75ra26. [CrossRef]
- Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung
Cancer. N Engl J Med 2017; 376: 629-40. [CrossRef]
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et
al. Identification of the transforming EML4 ALK fusion gene in non
small celllung cancer. Nature 2007; 448: 561-6. [CrossRef]
- Shames DS, Wistuba II. The evolving genomic classification of lung
cancer. J Pathol 2014; 232: 121-33. [CrossRef]
- Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib
versus chemotherapy in advanced ALK positive lung cancer. N
Engl J Med 2013; 368: 2385-94. [CrossRef]
- Solomon BJ, Mok T, Kim DW, Wu Y-L, Nakagawa K, Mekhail T, et al.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med 2014; 371: 2167-77. [CrossRef]
- Crino L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, et al. Multicenter
Phase II Study of Whole-Body and Intracranial Activity With
Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer
Previously Treated With Chemotherapy and Crizotinib: Results
From ASCEND-2. J Clin Oncol 2016; 34: 2866-73. [CrossRef]
- Felip E, Orlov S, Park K, Yu CJ,Tsai MC, Nishio M, et al. ASCEND-3:
A Single-Arm, Open-Label, ulticenter Phase II Study of Ceritinib in
ALKINaïve Adult Patients (pts) with ALKRearranged (ALK+) NonSmall
Cell Lung Cancer (NSCLC). J Clin Oncol 2015.
- Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al.
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell
Lung Cancer: A Phase II Global Study. J Clin Oncol 2016; 34: 661-8.
[CrossRef]
- Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib
versus crizotinib in patients with ALK-positive non-small-cell
lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet
2017; 390: 29-39. [CrossRef]
- Doebele RC. A nice problem to have: when ALK inhibitor therapy
works better than expected. J Thorac Oncol 2014; 9: 433-5. [CrossRef]
- Ou SHI, Bang YJ, Camidge DR, Riely GJ, Salgia R, Shapiro G, et al. Efficacy
and safety of crizotinib in patients with advanced ROS1 rearranged
non small cell lung cancer (NSCLC). J Clin Oncol 2013; 31.
- Minuti G, D’Incecco A, Cappuzzo F. Targeted therapy for NSCLC
with driver mutations. Expert Opin Biol Ther 2013; 13: 1401-12.
[CrossRef ]
- Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations
and primary resistance of lung adenocarcinomas to gefitinib
or erlotinib. PLoS Med 2005; 2: 17. [CrossRef]
- Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C,
et al. Selumetinib plus docetaxel for KRAS mutant advanced non
small cell lung cancer: A randomised, multicentre, placebo controlled,
phase 2 study. Lancet Oncol 2013; 14: 38-47 [CrossRef]
- Mason I. Initiation to end point: The multiple roles of fibroblast
growth factors in neural development. Nat Rev Neurosci 2007; 8:
583-96. [CrossRef]
- Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III
trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy
and docetaxel consolidation in inoperable stage III non
small cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26: 2450-6.
[CrossRef]
- Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V,
et al. Phase III trial of cisplatin plus gemcitabine with either placebo
or bevacizumab as first line therapy for nonsquamous non small cell
lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34. [CrossRef]
- Antonia SJ, Villegas A, Daniel D,Vicente D, Murakami S, Hui R, et al;
PACIFIC Investigators. Durvalumab after Chemoradiotherapy in
Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-
29. [CrossRef]
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A,
et al.Pembrolizumab versus Chemotherapy for PD-L1 Positive NonSmall-Cell
Lung Cancer. N Engl J Med 2016; 375: 1823-33. [CrossRef]
- Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik
A, Powell SF, et al. Carboplatin and pemetrexed with or without
pembrolizumab for advanced, non-squamous non-small-cell
lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021
study. Lancet Oncol 2016; 17: 1497-508. [CrossRef]
- Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al.
CFirst-line nivolumab in stage IV or recurrent non-small-cell lung
cancer. N Engl J Med 2017; 376: 2415-26. [CrossRef]
- Brahmer J, Reckamp KL, Baas P,Crino L, Eberhardt WEE, Poddusskaya
E, et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell
Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:
123-35. [CrossRef ]
- Kılıçalp S. Immunotherapy. Turkiye Klinikleri J Radiat Oncol-Special
Topics 2018; 4: 93-6.